Lunan Better Pharmaceutical Co., Ltd. · Small Molecule · Phase 2/3
ActiveTherapeutic
Population
Adults · 18–65 years
Recurrent unilateral Ménière’s disease
Evidence
trial
Confidence
88%
Indications
Hearing LossTinnitus
See what is being studies, who is developing it, and how far it has progressed.
Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.
A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.
How records are checked